PAMPs and DAMPs as triggers for DIC

Journal of Intensive Care

Volumn 2, Issue 1, 2014, Pages

  Ito, Takashi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Damage associated molecular patterns (DAMPs); Disseminated intravascular coagulation (DIC); Immunothrombosis; Neutrophil extracellular traps (NETs); Pathogen associated molecular patterns (PAMPs); Tissue factor

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; HEPARAN SULFATE; HIGH MOBILITY GROUP B1 PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; DAMAGE ASSOCIATED MOLECULAR PATTERN; DISSEMINATED INTRAVASCULAR CLOTTING; EXTRACELLULAR TRAP; HEMOSTASIS; HUMAN; IMMUNOTHROMBOSIS; INNATE IMMUNITY; MOLECULAR RECOGNITION; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; THROMBOSIS; TISSUE REPAIR;

EID: 84979196664     PISSN: None     EISSN: 20520492     Source Type: Journal    
DOI: 10.1186/s40560-014-0065-0     Document Type: Article

References (100)

1. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011, 364:1746-1760. 10.1056/NEJMra1011670, 21542745.
2. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2003, 1:1602-1612. 10.1046/j.1538-7836.2003.00267.x, 12871297.
3. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008, 359:938-949. 10.1056/NEJMra0801082, 18753650.
4. Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955, 34:602-613. 10.1172/JCI103109, 438666, 14367514.
5. Colman RW. Are hemostasis and thrombosis two sides of the same coin?. J Exp Med 2006, 203:493-495. 10.1084/jem.20060217, 2118234, 16533890.
6. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005, 202:271-281. 10.1084/jem.20050664, 2213000, 16009717.
7. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, Renne C, Gailani D, Nieswandt B, Renne T. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med 2006, 203:513-518. 10.1084/jem.20052458, 2118228, 16533887.
8. von Bruhl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, Khandoga A, Tirniceriu A, Coletti R, Kollnberger M, Byrne RA, Laitinen I, Walch A, Brill A, Pfeiler S, Manukyan D, Braun S, Lange P, Riegger J, Ware J, Eckart A, Haidari S, Rudelius M, Schulz C, Echtler K, Brinkmann V, Schwaiger M, Preissner KT, Wagner DD, Mackman N, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012, 209:819-835. 10.1084/jem.20112322, 3328366, 22451716.
9. Aird WC. Spatial and temporal dynamics of the endothelium. J Thromb Haemost 2005, 3:1392-1406. 10.1111/j.1538-7836.2005.01328.x, 15892866.
10. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol 2007, 7:803-815. 10.1038/nri2171, 17893694.
11. Esmon CT. The regulation of natural anticoagulant pathways. Science 1987, 235:1348-1352. 10.1126/science.3029867, 3029867.
12. Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999, 341:586-592. 10.1056/NEJM199908193410807, 10451465.
13. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013, 13:34-45. 10.1038/nri3345, 23222502.
14. Pfeiler S, Massberg S, Engelmann B. Biological basis and pathological relevance of microvascular thrombosis. Thromb Res 2014, 133(Suppl 1):S35-S37. 10.1016/j.thromres.2014.03.016, 24759139.
15. Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately?. Blood 2009, 114:2367-2374. 10.1182/blood-2009-05-199208, 19584396.
16. Muta T, Iwanaga S. The role of hemolymph coagulation in innate immunity. Curr Opin Immunol 1996, 8:41-47. 10.1016/S0952-7915(96)80103-8, 8729445.
17. Cerenius L, Soderhall K. Coagulation in invertebrates. J Innate Immun 2011, 3:3-8. 10.1159/000322066, 21051883.
18. Luo D, Szaba FM, Kummer LW, Plow EF, Mackman N, Gailani D, Smiley ST. Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica. J Immunol 2011, 187:1866-1876. 10.4049/jimmunol.1101094, 3150340, 21724997.
19. Sun H, Wang X, Degen JL, Ginsburg D. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 2009, 113:1358-1364. 10.1182/blood-2008-07-170506, 2637198, 19056689.
20. Massberg S, Grahl L, von Bruehl ML, Manukyan D, Pfeiler S, Goosmann C, Brinkmann V, Lorenz M, Bidzhekov K, Khandagale AB, Konrad I, Kennerknecht E, Reges K, Holdenrieder S, Braun S, Reinhardt C, Spannagl M, Preissner KT, Engelmann B. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010, 16:887-896. 10.1038/nm.2184, 20676107.
21. Günther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-WollbrÜCk B, Seeger W. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Am J Resp Crit Care Med 2000, 161:454-462. 10.1164/ajrccm.161.2.9712038, 10673185.
22. Wong CH, Jenne CN, Petri B, Chrobok NL, Kubes P. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. Nat Immunol 2013, 14:785-792. 10.1038/ni.2631, 23770641.
23. Vieira-de-Abreu A, Campbell RA, Weyrich AS, Zimmerman GA. Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum. Semin Immunopathol 2012, 34:5-30. 10.1007/s00281-011-0286-4, 4334392, 21818701.
24. Gross AK, Dunn SP, Feola DJ, Martin CA, Charnigo R, Li Z, Abdel-Latif A, Smyth SS. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness. J Thromb Thrombolysis 2013, 35:147-154. 10.1007/s11239-012-0833-4, 3732820, 23124575.
25. Winning J, Reichel J, Eisenhut Y, Hamacher J, Kohl M, Deigner HP, Claus RA, Bauer M, Lösche W. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets 2009, 20:50-57. 10.1080/09537100802503368, 19172522.
26. Winning J, Neumann J, Kohl M, Claus RA, Reinhart K, Bauer M, Losche W. Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med 2010, 38:32-37. 10.1097/CCM.0b013e3181b4275c, 19770746.
27. Loof TG, Morgelin M, Johansson L, Oehmcke S, Olin AI, Dickneite G, Norrby-Teglund A, Theopold U, Herwald H. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 2011, 118:2589-2598. 10.1182/blood-2011-02-337568, 21613262.
28. Flick MJ, Du X, Witte DP, Jirouskova M, Soloviev DA, Busuttil SJ, Plow EF, Degen JL. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest 2004, 113:1596-1606. 10.1172/JCI20741, 419487, 15173886.
29. Frick IM, Akesson P, Herwald H, Morgelin M, Malmsten M, Nagler DK, Bjorck L. The contact system-a novel branch of innate immunity generating antibacterial peptides. EMBO J 2006, 25:5569-5578. 10.1038/sj.emboj.7601422, 1679765, 17093496.
30. Rivers RP, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol 1975, 30:311-316. 10.1111/j.1365-2141.1975.tb00547.x, 1201214.
31. Egorina EM, Sovershaev MA, Bjørkøy G, Gruber FXE, Olsen JO, Parhami-Seren B, Mann KG, Østerud B. Intracellular and surface distribution of monocyte tissue factor: application to intersubject variability. Arterioscler Thromb Vasc Biol 2005, 25:1493-1498. 10.1161/01.ATV.0000168413.29874.d7, 1410195, 15860742.
32. Pawlinski R, Pedersen B, Schabbauer G, Tencati M, Holscher T, Boisvert W, Andrade-Gordon P, Frank RD, Mackman N. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood 2004, 103:1342-1347. 10.1182/blood-2003-09-3051, 2860856, 14576054.
33. Pawlinski R, Wang JG, Owens AP, Williams J, Antoniak S, Tencati M, Luther T, Rowley JW, Low EN, Weyrich AS, Mackman N. Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. Blood 2010, 116:806-814. 10.1182/blood-2009-12-259267, 2918334, 20410508.
34. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science 2004, 303:1532-1535. 10.1126/science.1092385, 15001782.
35. Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 2007, 5:577-582. 10.1038/nrmicro1710, 17632569.
36. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD, Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010, 107:15880-15885. 10.1073/pnas.1005743107, 2936604, 20798043.
37. Martinod K, Wagner DD. Thrombosis: tangled up in NETs. Blood 2014, 123:2768-2776. 10.1182/blood-2013-10-463646, 24366358.
38. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, Patel KD, Chakrabarti S, McAvoy E, Sinclair GD, Keys EM, Allen-Vercoe E, Devinney R, Doig CJ, Green FH, Kubes P. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007, 13:463-469. 10.1038/nm1565, 17384648.
39. Gould TJ, Vu T, Swystun LL, Dwivedi D, Mai S, Weitz JI, Liaw PC. Neutrophil extracellular traps promote thrombin generation through platelet-dependent and platelet-independent mechanisms. Arterioscler Thromb Vasc Biol 2014, 34:1977-1984. 10.1161/ATVBAHA.114.304114, 25012129.
40. McDonald B, Urrutia R, Yipp BG, Jenne CN, Kubes P. Intravascular neutrophil extracellular traps capture bacteria from the bloodstream during sepsis. Cell Host Microbe 2012, 12:324-333. 10.1016/j.chom.2012.06.011, 22980329.
41. Beiter K, Wartha F, Albiger B, Normark S, Zychlinsky A, Henriques-Normark B. An endonuclease allows Streptococcus pneumoniae to escape from neutrophil extracellular traps. Curr Biol 2006, 16:401-407. 10.1016/j.cub.2006.01.056, 16488875.
42. Walker MJ, Hollands A, Sanderson-Smith ML, Cole JN, Kirk JK, Henningham A, McArthur JD, Dinkla K, Aziz RK, Kansal RG, Simpson AJ, Buchanan JT, Chhatwal GS, Kotb M, Nizet V. DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat Med 2007, 13:981-985. 10.1038/nm1612, 17632528.
43. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305. 10.1126/science.1071059, 11951032.
44. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008, 8:279-289. 10.1038/nri2215, 2763408, 18340345.
45. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826. 10.1038/nature06246, 17943118.
46. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010, 10:826-837. 10.1038/nri2873, 3114424, 21088683.
47. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195. 10.1038/nature00858, 12110890.
48. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Muller S, Iannacone M, Traversari C, Bianchi ME, Manfredi AA. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004, 5:825-830. 10.1038/sj.embor.7400205, 1299116, 15272298.
49. Huang H, Evankovich J, Yan W, Nace G, Zhang L, Ross M, Liao X, Billiar T, Xu J, Esmon CT, Tsung A. Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice. Hepatology 2011, 54:999-1008. 10.1002/hep.24501, 3213322,3213322, 21721026.
50. McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, Waterhouse CC, Beck PL, Muruve DA, Kubes P. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010, 330:362-366. 10.1126/science.1195491, 20947763.
51. Trautmann A. Extracellular ATP in the immune system: more than just a "danger signal". Sci Signal 2009, 2:pe6. 10.1126/scisignal.256pe6, 19193605.
52. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521. 10.1038/nature01991, 14520412.
53. Kono H, Chen CJ, Ontiveros F, Rock KL. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest 2010, 120:1939-1949. 10.1172/JCI40124, 2877935, 20501947.
54. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464:104-107. 10.1038/nature08780, 2843437, 20203610.
55. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010, 140:798-804. 10.1016/j.cell.2010.02.015, 20303871.
56. Ito T, Kawahara K, Nakamura T, Yamada S, Nakamura T, Abeyama K, Hashiguchi T, Maruyama I. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost 2007, 5:109-116. 10.1111/j.1538-7836.2006.02255.x, 17239166.
57. Furlan-Freguia C, Marchese P, Gruber A, Ruggeri ZM, Ruf W. P2X7 receptor signaling contributes to tissue factor-dependent thrombosis in mice. J Clin Invest 2011, 121:2932-2944. 10.1172/JCI46129, 3127437, 21670495.
58. Reinhardt C, von Bruhl ML, Manukyan D, Grahl L, Lorenz M, Altmann B, Dlugai S, Hess S, Konrad I, Orschiedt L, Mackman N, Ruddock L, Massberg S, Engelmann B. Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation. J Clin Invest 2008, 118:1110-1122. 2242616, 18274674.
59. Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. Blood 2011, 118:3708-3714. 10.1182/blood-2011-01-332676, 3186342, 21700775.
60. Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest 2005, 128:2864-2875. 10.1378/chest.128.4.2864, 16236964.
61. Hunt BJ. Bleeding and coagulopathies in critical care. New Engl J Med 2014, 370:847-859. 10.1056/NEJMra1208626, 24571757.
62. Taylor FB, Chang AC, Peer G, Li A, Ezban M, Hedner U. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood 1998, 91:1609-1615.
63. Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost 1983, 49:5-7.
64. Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, Cossu G, Bianchi ME. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 2004, 164:441-449. 10.1083/jcb.200304135, 2172232, 14744997.
65. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251. 10.1126/science.285.5425.248, 10398600.
66. Hatada T, Wada H, Nobori T, Okabayashi K, Maruyama K, Abe Y, Uemoto S, Yamada S, Maruyama I. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005, 94:975-979.
67. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE, Susarla SM, Ulloa L, Wang H, DiRaimo R, Czura CJ, Wang H, Roth J, Warren HS, Fink MP, Fenton MJ, Andersson U, Tracey KJ. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 2004, 101:296-301. 10.1073/pnas.2434651100, 314179, 14695889.
68. Abeyama K, Stern DM, Ito Y, Kawahara KI, Yoshimoto Y, Tanaka M, Uchimura T, Ida N, Yamazaki Y, Yamada S, Yamamoto Y, Yamamoto H, Iino S, Taniguchi N, Maruyama I. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005, 115:1267-1274. 10.1172/JCI22782, 1077171, 15841214.
69. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB, Esmon NL, Lupu F, Esmon CT. Extracellular histones are major mediators of death in sepsis. Nat Med 2009, 15:1318-1321. 10.1038/nm.2053, 2783754, 19855397.
70. Nakahara M, Ito T, Kawahara KI, Yamamoto M, Nagasato T, Shrestha B, Yamada S, Miyauchi T, Higuchi K, Takenaka T, Yasuda T, Matsunaga A, Kakihana Y, Hashiguchi T, Kanmura Y, Maruyama I. Recombinant thrombomodulin protects mice against histone-induced lethal thromboembolism. PLoS ONE 2013, 8:e75961. 10.1371/journal.pone.0075961, 3786915, 24098750.
71. Bamboat ZM, Balachandran VP, Ocuin LM, Obaid H, Plitas G, De Matteo RP. Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury. Hepatology 2010, 51:621-632. 10.1002/hep.23365, 3164814, 19902481.
72. Dwivedi DJ, Toltl LJ, Swystun LL, Pogue J, Liaw KL, Weitz JI, Cook DJ, Fox-Robichaud AE, Liaw PC. Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Crit Care 2012, 16:R151. 10.1186/cc11466, 3580740, 22889177.
73. De Vlaminck I, Khush KK, Strehl C, Kohli B, Luikart H, Neff NF, Okamoto J, Snyder TM, Cornfield DN, Nicolls MR, Weill D, Bernstein D, Valantine HA, Quake SR. Temporal response of the human virome to immunosuppression and antiviral therapy. Cell 2013, 155:1178-1187. 10.1016/j.cell.2013.10.034, 4098717, 24267896.
74. Swystun LL, Mukherjee S, Liaw PC. Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost 2011, 9:2313-2321. 10.1111/j.1538-7836.2011.04465.x, 21838758.
75. Meng W, Paunel-Gorgulu A, Flohe S, Hoffmann A, Witte I, Mackenzie C, Baldus SE, Windolf J, Logters TT. Depletion of neutrophil extracellular traps in vivo results in hypersusceptibility to polymicrobial sepsis in mice. Crit Care 2012, 16:R137. 10.1186/cc11442, 3580722, 22835277.
76. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, Laszik Z, Esmon CT, Heyderman RS. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001, 345:408-416. 10.1056/NEJM200108093450603, 11496851.
77. Niessen RW, Lamping RJ, Jansen PM, Prins MH, Peters M, Taylor FB, de Vijlder JJ, ten Cate JW, Hack CE, Sturk A. Antithrombin acts as a negative acute phase protein as established with studies on HepG2 cells and in baboons. Thromb Haemost 1997, 78:1088-1092.
78. Opal SM. Therapeutic rationale for antithrombin III in sepsis. Crit Care Med 2000, 28:S34-S37. 10.1097/00003246-200009001-00008, 11007195.
79. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41:580-637. 10.1097/CCM.0b013e31827e83af, 23353941.
80. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002, 296:1880-1882. 10.1126/science.1071699, 12052963.
81. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. New Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001, 11236773.
82. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto T, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. New Engl J Med 2005, 353:1332-1341. 10.1056/NEJMoa050935, 16192478.
83. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007, 369:836-843. 10.1016/S0140-6736(07)60411-5, 17350452.
84. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD. Drotrecogin alfa (activated) in adults with septic shock. New Engl J Med 2012, 366:2055-2064. 10.1056/NEJMoa1202290, 22616830.
85. Mitka M. Drug for severe sepsis is withdrawn from market, fails to reduce mortality. JAMA 2011, 306:2439-2440.
86. Isermann B, Hendrickson SB, Zogg M, Wing M, Cummiskey M, Kisanuki YY, Yanagisawa M, Weiler H. Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J Clin Invest 2001, 108:537-546. 10.1172/JCI200113077, 209404, 11518727.
87. Ito T, Maruyama I. Thrombomodulin: protectorate God of the vasculature in thrombosis and inflammation. J Thromb Haemost 2011, 9(Suppl 1):168-173. 10.1111/j.1538-7836.2011.04319.x, 21781252.
88. Shi CS, Shi GY, Hsiao SM, Kao YC, Kuo KL, Ma CY, Kuo CH, Chang BI, Chang CF, Lin CH, Wong CH, Wu HL. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 2008, 112:3661-3670. 10.1182/blood-2008-03-142760, 2572793, 18711002.
89. Ito T, Kawahara K, Okamoto K, Yamada S, Yasuda M, Imaizumi H, Nawa Y, Meng X, Shrestha B, Hashiguchi T, Maruyama I. Proteolytic cleavage of high mobility group box 1 protein by thrombin-thrombomodulin complexes. Arterioscler Thromb Vasc Biol 2008, 28:1825-1830. 10.1161/ATVBAHA.107.150631, 18599803.
90. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:345-357. 10.1056/NEJMoa0810739, 3530919, 19625716.
91. Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, Weitz JI, Weiler H, Hellings PW, Schaeffer P, Herbert JM, Collen D, Theilmeier G. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002, 196:565-577. 10.1084/jem.20020077, 2193995, 12208873.
92. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, Aoki N. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007, 5:31-41. 10.1111/j.1538-7836.2006.02267.x, 17059423.
93. Ogawa Y, Yamakawa K, Ogura H, Kiguchi T, Mohri T, Nakamori Y, Kuwagata Y, Shimazu T, Hamasaki T, Fujimi S. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg 2012, 72:1150-1157.
94. Yamakawa K, Fujimi S, Mohri T, Matsuda H, Nakamori Y, Hirose T, Tasaki O, Ogura H, Kuwagata Y, Hamasaki T, Shimazu T. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study. Crit Care 2011, 15:R123. 10.1186/cc10228, 3218981, 21569368.
95. Yamakawa K, Ogura H, Fujimi S, Morikawa M, Ogawa Y, Mohri T, Nakamori Y, Inoue Y, Kuwagata Y, Tanaka H, Hamasaki T, Shimazu T. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med 2013, 39:644-652. 10.1007/s00134-013-2822-2, 3607733, 23361628.
96. Vincent JL, Ramesh MK, Ernest D, Larosa SP, Pachl J, Aikawa N, Hoste E, Levy H, Hirman J, Levi M, Daga M, Kutsogiannis DJ, Crowther M, Bernard GR, Devriendt J, Puigserver JV, Blanzaco DU, Esmon CT, Parrillo JE, Guzzi L, Henderson SJ, Pothirat C, Mehta P, Fareed J, Talwar D, Tsuruta K, Gorelick KJ, Osawa Y, Kaul I. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 2013, 41:2069-2079. 10.1097/CCM.0b013e31828e9b03, 23979365.
97. Hoffmann JN, Vollmar B, Laschke MW, Inthorn D, Kaneider NC, Dunzendorfer S, Wiedermann CJ, Romisch J, Schildberg FW, Menger MD. Adverse effect of heparin on antithrombin action during endotoxemia: microhemodynamic and cellular mechanisms. Thromb Haemost 2002, 88:242-252.
98. Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, Knaub S, Keinecke HO, Heinrichs H, Schindel F, Juers M, Bone RC, Opal SM. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286:1869-1878. 10.1001/jama.286.15.1869, 11597289.
99. Kienast J, Juers M, Wiedermann CJ, Hoffmann JN, Ostermann H, Strauss R, Keinecke HO, Warren BL, Opal SM. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost 2006, 4:90-97. 10.1111/j.1538-7836.2005.01697.x, 16409457.
100. Wiedermann CJ, Hoffmann JN, Juers M, Ostermann H, Kienast J, Briegel J, Strauss R, Keinecke HO, Warren BL, Opal SM. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 2006, 34:285-292. 10.1097/01.CCM.0000194731.08896.99, 16424704.